Genen­tech inks $359M deal with Kine­ta; Celldex bat­tered af­ter ADC flops in PhI­Ib

→ Genen­tech is com­mit­ting up to $359 mil­lion to pur­sue a nov­el tar­get for chron­ic neu­ro­path­ic pain. Their part­ner in this ex­clu­sive op­tion and li­cense agree­ment is Seat­tle-based Kine­ta Chron­ic Pain, which will be de­vel­op­ing α9/α10 nico­tinic acetyl­choline re­cep­tor (nAChR) an­tag­o­nists for the col­lab­o­ra­tion un­til Genen­tech steps in to grab de­vel­op­ment and com­mer­cial­iza­tion rights. Kine­ta be­lieves that the tar­get may lead to a “safer ther­a­py that is non-ad­dic­tive and non-to­ler­iz­ing.” The break­down be­tween up­front and mile­stones was not dis­closed, though we do know that Kine­ta is in for high sin­gle to low dou­ble-dig­it roy­al­ties if the as­sets ever make it to mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER